Measuring US pharmaceutical industry R&D spending

PharmacoEconomics

Volumn 26, Issue 12, 2008, Pages 1005-1017

  Golec, Joseph ^a   Vernon, John ^a,b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b IL   (United States)

Author keywords

Cost analysis; Research and development

Indexed keywords

DRUG;

COST BENEFIT ANALYSIS; DATA ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG INDUSTRY; DRUG RESEARCH; GOVERNMENT; HEALTH CARE FINANCING; HEALTH CARE POLICY; HUMAN; PRIORITY JOURNAL; RELIABILITY; REVIEW; UNITED STATES;

BIOMEDICAL TECHNOLOGY; DATABASES, FACTUAL; DRUG INDUSTRY; RESEARCH; UNITED STATES;

EID: 56549117147     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/0019053-200826120-00004     Document Type: Review

References (29)

1. Giaccotto C, Santerre R, Vernon J. Drug prices and research and development investment behavior in the pharmaceutical industry. J Law Econ 2005; 48: 195-214
2. Light D, Lexchin J. Will lower drug prices jeopardize drug research? A policy fact sheet. Am J Bioeth 2004; 4: W1-4
3. Light D, Warburton R. Extraordinary claims require extraordinary evidence. J Health Econ 2005; 24: 1030-3
4. Public Citizen. America's other drug problem: a briefing book on the Rx drug debate. Washington, DC: Public Citizen Congress Watch, 2003
5. Public Citizen. Rx R&D myths: the case against the drug industry's R&D scare card. Washington, DC: Public Citizen Congress Watch, 2001 Jul
6. Angell M. The truth about the drug companies: how they deceive us and what to do about it. New York: Random House Publishing Group, 2004
7. Golec J, Vernon J. New estimates of pharmaceutical research and development spending by US-based firms from 1984 to 2003. Managerial Decision Econ 2007; 28: 481-3
8. Cockburn I. The changing structure of the pharmaceutical industry. Health Aff 2004; 23: 10-22
9. Okunade A, Murthy V. Technology as a 'major driver' of health care costs: a cointegration analysis of the Newhouse conjecture. J Health Econ 2002; 21: 147-59
10. Zinner D. Medical R&D at the turn of the millennium. Health Aff 2001; 20: 202-9
11. Scherer F. The pharmaceutical industry: prices and progress. N Engl J Med 2004; 351: 927-32
12. Lichtenberg F. The private Rand D investment response to federal design and technical competitions. Am Econ Rev 1986; 78: 550-9
13. Griliches Z. Productivity, R&D, and the data constraint. Am Econ Rev 1994; 84: 1-23
14. Cockburn I, Griliches Z. Industry effects and appropriability measures in the stock market's valuation of R&D and patents. Am Econ Rev 1988; 78: 419-23
15. Waring G. Industry differences in persistence of firm-specific returns. Am Econ Rev 1996; 86: 1253-65
16. PhRMA. Pharmaceutical Industry Profile 2005 [online]. Available from URL: http://members.phrma.org/publications/publications/17.03.2005.1142.cfm [Accessed 2008 Oct 2]
17. National Science Foundation: Bureau of Census. Survey of Industrial Research and Development [online]. Available from URL: http://www.nsf.gov/ statistics/srvyindustry/ [Accessed 2008 Sep 26]
18. National Science Foundation. Industrial research and development information system: historical data 1953-98 [online]. Available from URL: http://www.nsf.gov/statistics/iris/search_hist.cfm?indx=10 [Accessed 2005 Dec 21]
19. National Science Foundation [online]. Available from URL: http://www.nsf.gov/statistics/nsf07314/content.cfm?pub_id=2488&id=2 [Accessed 2005 Dec 21]
20. National Science Foundation. Industrial research and development information system: historical data 1953-98 [online]. Available from URL: http://www.nsf.gov/statistics/iris/search_hist.cfm?indx=27 [Accessed 2005 Dec 21]
21. National Science Foundation. Industrial research and development information system: historical data 1953-98 [online]. Available from URL: http://www.nsf.gov/statistics/iris/search_hist.cfm?indx=12 [Accessed 2005 Dec 21]
22. US Department of Commerce. Bureau of Economic Analysis: International Economic Accounts. Foreign direct investment in the US: financial and operating data for US affiliates of foreign multinational companies [online]. Available from URL: http://www.bea.gov/bea/di/di1fdiop.htm [Accessed 2006 Mar 12]
23. Hall B, Long W. Differences in reporting R&D data on the NSF/Census RD-1 form and the SEC 10-K form: a micro-data investigation, report to the National Science Foundation; 1999 [online]. Available from URL: http://elsa.berkeley.edu/~bhhall/papers/HallLong99%20R&Ddata.pdf [Accessed 2008 Sep 25]
24. National Science Foundation. Survey of industrial research and development [online]. Available from URL: http://www. nsf.gov/statistics/ showsrvy.cfm?srvy_CatID=4&srvy_Seri=13 [Accessed 2005 Dec 21]
25. National Science Foundation. Increase in US R&D expenditures reported for 2003 makes up for earlier decline [online]. Available from URL: www.nsf.gov/statistics/infbrief/nsf06305/nsf06305.pdf [Accessed 2005 Dec 21]
26. US Food and Drug Administration, Center for Drug Evaluation and Research. CDER original INDs received: calendar years 1986-2006 [online]. Available from URL: http://www.fda.gov/cder/rdmt/Cyindrec.htm [Accessed 2005 Dec 21]
27. US Securities and Exchange Commission. Electronic Data Gathering, Analysis and Retrieval (EDGAR) system [online]. Available from URL: http://www.sec.gov/edgar.shtml [Accessed 2008 Sep 26]
28. European Federation of Pharmaceutical Industries and Associations (EFPIA). The pharmaceutical industry in figures. Brussels: EFPIA, 2005
29. Owens J, for the Office for National Statistics. Research and experimental development (R&D) statistics, 2003. Econ Trends 2005 Aug; 621: 28-52 [online]. Available from URL: http://www.statistics.gov.uk/articles/ economic_trends/et621_owen.pdf [Accessed 2008 Sep 25]